Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurelien Belot, Emmanuel Bachy, Herve Ghesquieres, François-Xavier Gros, Krimo Bouabdallah, Guillaume Cartron, Roberta Di Blasi, Roch Houot, Cedric Rossi, Amandine Durand, Fabien Le Bras, Corinne Haioun, Thomas Gastinne, Remy Dulery, Pierre Bories, Fabrice Jardin, Blandine Guffroy, Luc-Matthieu Fornecker, Cristina Castilla-Llorente, Gandhi Damaj, Franck Morschhauser, Michael Loschi, Stephanie Guidez, Choquet Sylvain, Aline Schmidt, Laurianne Drieu La Rochelle, Marie-Thérèse Rubio, Sylvain Carras, Jacques-Olivier Bay, Adrien Chauchet, Magalie Joris, Ludovic Fouillet, Laure Lebras, Julie Abraham, Fontanet Bijou, Olivier Hermine, Antoine Bonnet, Justine Decroocq, Sandy Amorim, Nadine Morineau, Pauline Lionne, Sophie Dennetiere, Laura Herbreteau, Bernard Drenou, Launay Vincent, Gaelle Olivier, Gaëlle Labouré, Olivier Fitoussi, Christophe Fruchart, Cecile Leyronnas, Fanny Cherblanc, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2025-2764

Published: 2025

Journal Articles

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2025-2745

Published: 2025

Journal Articles

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

Stephanie Guidez, Marie-Thérèse Rubio, Roberta Di Blasi, Gabriel Brisou, Morgane Cheminant, Emmanuel Bachy, Franck Morschhauser, Cristina Castilla-Llorente, Blandine Guffroy, Roch Houot, Steven Le Gouill, Olivier Hermine, Fabien Le Bras, Laure Ricard, Damien Roos Weil

Blood (2025) 146 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2025-3598

Published: 2025

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Blood (2025) 146 (Supplement 1): 5490.

https://doi.org/10.1182/blood-2025-5490

Published: 2025

Journal Articles

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 127.

https://doi.org/10.1182/blood-2025-127

Published: 2025

Journal Articles

Prognostic value of baseline metabolic tumor volume from lysa ro-CHOP trial inpatients with previously untreated peripheral T-cell lymphoma

Jules Zhang-Yin, Anne Ségolène Cottereau, Romain Ould-Ammar, Loïc Chartier, Romain Ricci, Catherine Thieblemont, David Sibon, Olivier Casasnovas, Loic Ysebaert, Gandhi Damaj, Stephanie Guidez, Gian Matteo Pica, Marc Andre, Philippe Gaulard, Marie-Helene Delfau-Larue, Franck Morschhauser, Richard Delarue, Vincent Camus, Emmanuel Bachy

Blood (2025) 146 (Supplement 1): 894.

https://doi.org/10.1182/blood-2025-894

Published: 2025

Journal Articles

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Blood (2025) 146 (Supplement 1): 956.

https://doi.org/10.1182/blood-2025-956

Published: 2025

Journal Articles

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Blood (2025) 146 (8): 913–925.

https://doi.org/10.1182/blood.2024027727

Published: 2025

Includes: Supplemental data

Journal Articles

A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry

Blood (2024) 144 (Supplement 1): 3129.

https://doi.org/10.1182/blood-2024-203186

Published: 2024

Journal Articles

The Combination of Isatuximab with Pomalidomide and Dexamethasone in Second Line Relapse and Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7041.

https://doi.org/10.1182/blood-2024-210687

Published: 2024

Journal Articles

Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry

Blood (2024) 144 (Supplement 1): 528.

https://doi.org/10.1182/blood-2024-208304

Published: 2024

Journal Articles

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Marion Aymard, Morgane Cheminant, Roch Houot, Anne Cuozzo, Elodie Gat, Catherine Thieblemont, Laure Ricard, Louise Roulin, Krimo Bouabdallah, Violaine Safar, Stephanie Guidez, Amandine Fayard, Gabriel Brisou, Loic Ysebaert, Olivier Hermine, Benoit Tessoulin, Charles Herbaux, Steven Le Gouill, Clementine Sarkozy

Blood (2024) 144 (Supplement 1): 239.

https://doi.org/10.1182/blood-2024-198920

Published: 2024

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Blood (2024) 143 (26): 2804–2807.

https://doi.org/10.1182/blood.2024024452

Published: 2024

Includes: Supplemental data

Journal Articles

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Blood (2024) 143 (11): 983–995.

https://doi.org/10.1182/blood.2023021564

Published: 2024

Includes: Supplemental data

Journal Articles

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Blood (2023) 142 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2023-189296

Published: 2023

Journal Articles

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Eric Durot, Damien Roos-Weil, Adrien Chauchet, Justine Decroocq, Roberta Di Blasi, Thomas Gastinne, Hedi Bensader, Morgane Cheminant, Caroline Jacquet, Stephanie Guidez, François-Xavier Gros, Emmanuel Bachy, Pascale Cony-Makhoul, Steven P Treon, Alain Jacques Delmer, Ran Reshef, Steven Le Gouill, Jorge J. Castillo, Roch Houot

Blood (2023) 142 (Supplement 1): 616.

https://doi.org/10.1182/blood-2023-173988

Published: 2023

Journal Articles

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 228.

https://doi.org/10.1182/blood-2023-185035

Published: 2023

Journal Articles

Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide S trategy for Innovative Clinical Trials

Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, Herve Ghesquieres, Frederic Peyrade, Fabrice Jardin, Stephanie Guidez, Fontanet Delices Bijou, Pierre Sesques, Cédric Rossi, Luc Matthieu Fornecker, Ludovic Fouillet, Sylvain Carras, Benoit Tessoulin

Blood (2023) 142 (Supplement 1): 72.

https://doi.org/10.1182/blood-2023-177708

Published: 2023

Journal Articles

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry

Blood (2023) 142 (Supplement 1): 5138.

https://doi.org/10.1182/blood-2023-180241

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Prognostic value of baseline metabolic tumor volume from lysa ro-CHOP trial inpatients with previously untreated peripheral T-cell lymphoma

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry

The Combination of Isatuximab with Pomalidomide and Dexamethasone in Second Line Relapse and Refractory Multiple Myeloma

Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide S trategy for Innovative Clinical Trials

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only